|
| Scenario | Base case value in Italy | Base case value in Spain | Base case value in Sweden | Effect |
|
| Duration of partial remission following first-line treatment with doxorubicin/ifosfamide ranges from 6.1 to 9.2 months | 7.7 months | 7.7 months | 7.7 months | Doxorubicin/ifosfamide remains a dominant treatment |
| Duration of stable disease following first-line treatment with doxorubicin/ifosfamide ranges from 5.1 to 7.7 months | 6.4 months | 6.4 months | 6.4 months | Doxorubicin/ifosfamide remains a dominant treatment |
| Duration of partial remission following first-line treatment with trabectedin ranges from 7.0 to 10.6 months | 8.8 months | 8.8 months | 8.8 months | Doxorubicin/ifosfamide remains a dominant treatment |
| Duration of stable disease following first-line treatment with trabectedin ranges from 6.0 to 9.0 months | 7.5 months | 7.5 months | 7.5 months | Doxorubicin/ifosfamide remains a dominant treatment |
| Probability of being in stable disease after first-line doxorubicin/ifosfamide ranges from 0.3 to 0.5 | 0.38 | 0.38 | 0.38 | Doxorubicin/ifosfamide remains a dominant treatment |
| Probability of being in stable disease after first-line trabectedin ranges from 0.1 to 0.2 | 0.14 | 0.14 | 0.14 | Doxorubicin/ifosfamide remains a dominant treatment |
| Probability of being in stable disease after second-line trabectedin ranges from 0.35 to 0.50 | 0.44 | 0.44 | 0.44 | Doxorubicin/ifosfamide remains a dominant treatment |
| Probability of switching to trabectedin after first-line doxorubicin/ifosfamide ranges from 80% below to 20% above the base case value | 0.50 | 0.26 | 0.30 | Doxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from being dominant to €21,500 per QALY, breaking even at a probability of 0.55 |
| Length of hospital stay for doxorubicin/ifosfamide infusion ranges from 1 to 5 days | 3 days | 4 days | 3 days | Doxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from being dominant to €16,400 per QALY, breaking even at 4 days |
| Unit cost of doxorubicin ranges from 80% below to 20% above the base case value | €119.50 | €4.11 | €59.79 | Doxorubicin/ifosfamide remains a dominant treatment |
| Unit cost of ifosfamide ranges from 80% below to 20% above the base case value | €30.71 | €19.71 | €65.65 | Doxorubicin/ifosfamide remains a dominant treatment |
| Unit cost of trabectedin ranges from 80% below to 20% above the base case value | €2,970.10 | €2,049.91 | €1,913.29 | Doxorubicin/ifosfamide remains a dominant treatment except in Italy where its costeffectiveness ranges from €11,200 per QALY to being dominant, breaking even at €2,570 |
| Cost of managing adverse events ranges from 80% below to 20% above the base case values | | | | Doxorubicin/ifosfamide remains a dominant treatment |
| Cost of pre- and postchemotherapy medications ranges from 80% below to 20% above the base case values | | | | Doxorubicin/ifosfamide remains a dominant treatment |
| Cost of palliative care ranges from 80% below to 20% above the base case values | | | | Doxorubicin/ifosfamide remains a dominant treatment |
| Utility for progressive disease ranges from 0.24 to 0.36 | 0.30 | 0.30 | 0.30 | Doxorubicin/ifosfamide remains a dominant treatment |
| Utility for stable disease ranges from 0.34 to 0.52 | 0.43 | 0.43 | 0.43 | Doxorubicin/ifosfamide remains a dominant treatment |
| Difference in QALYs gained following the start of treatment with doxorubicin/ifosfamide and trabectedin ranges from 80% below and 20% above the base case value | 0.07 | 0.04 | 0.02 | Doxorubicin/ifosfamide remains a dominant treatment |
|
